Symphogen loses Chief Scientific Officer - silent about possible successor
For seven years, American Ivan Horak was responsible for global research and development in Symphogen. Now, he has left his position in favor of a Singapore-based biotech firm, but he continues as scientific advisor the Danish company that declines to reveal whether it is looking for a successor.
Since 2011, Ivan D. Horak has led all research and development in Danish biotech company Symphogen in his position as Head of Global Research and Development, Chief Scientific and Medical Officer.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
